Your browser doesn't support javascript.
loading
Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples.
Suzuki, Kuno; Yamaguchi, Tatsuya; Kohda, Masakazu; Tanaka, Masami; Takemura, Hiroyuki; Wakita, Mitsuru; Tabe, Yoko; Kato, Shunsuke; Nasu, Motomi; Hashimoto, Takashi; Mine, Shinji; Serizawa, Nobuko; Tomishima, Ko; Nagahara, Akihito; Matsuda, Takahisa; Yamaji, Taiki; Tsugane, Shoichiro; Saito, Yutaka; Daiko, Hiroyuki; Yoshikawa, Takaki; Kato, Ken; Okusaka, Takuji; Ochiya, Takahiro; Yamamoto, Yusuke; Yotsui, Shoji; Yamamoto, Takashi; Yamasaki, Tomoyuki; Miyata, Hiroshi; Yasui, Masayoshi; Omori, Takeshi; Ohkawa, Kazuyoshi; Ikezawa, Kenji; Nakabori, Tasuku; Sugimoto, Naotoshi; Kudo, Toshihiro; Yoshida, Keiichi; Ohue, Masayuki; Nishizawa, Takashi.
Afiliación
  • Suzuki K; Healthcare Business Department, PFDeNA, Inc., Tokyo, Japan.
  • Yamaguchi T; Healthcare Business Department, PFDeNA, Inc., Tokyo, Japan.
  • Kohda M; Healthcare Business Department, PFDeNA, Inc., Tokyo, Japan.
  • Tanaka M; Healthcare Business Department, PFDeNA, Inc., Tokyo, Japan.
  • Takemura H; Department of Clinical Laboratory, Juntendo University Hospital, Tokyo, Japan.
  • Wakita M; Department of Clinical Laboratory, Juntendo University Hospital, Tokyo, Japan.
  • Tabe Y; Department of Clinical Laboratory, Juntendo University Hospital, Tokyo, Japan.
  • Kato S; Department of Clinical Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Nasu M; Department of Esophageal and Gastroenterological Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Hashimoto T; Department of Esophageal and Gastroenterological Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Mine S; Department of Esophageal and Gastroenterological Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Serizawa N; Department of Gastroenterology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Tomishima K; Department of Gastroenterology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Nagahara A; Department of Gastroenterology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Matsuda T; Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan.
  • Yamaji T; Division of Epidemiology, National Cancer Center Institute for Cancer Control, Tokyo, Japan.
  • Tsugane S; Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan.
  • Saito Y; Department of Endoscopy, National Cancer Center Hospital, Tokyo, Japan.
  • Daiko H; Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • Yoshikawa T; Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • Kato K; Department of Head and Neck, Esophageal Medical Oncology / Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Ochiya T; Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Yamamoto Y; Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Yotsui S; Clinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
  • Yamamoto T; Clinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
  • Yamasaki T; Clinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
  • Miyata H; Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
  • Yasui M; Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
  • Omori T; Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
  • Ohkawa K; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Ikezawa K; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Nakabori T; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Sugimoto N; Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Kudo T; Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Yoshida K; Next-generation Precision Medicine Research Center, Osaka International Cancer Institute, Osaka, Japan.
  • Ohue M; Next-generation Precision Medicine Research Center, Osaka International Cancer Institute, Osaka, Japan.
  • Nishizawa T; Healthcare Business Department, PFDeNA, Inc., Tokyo, Japan.
PLoS One ; 17(12): e0278927, 2022.
Article en En | MEDLINE | ID: mdl-36516194
ABSTRACT
The relationship between the expression of microRNAs (miRNAs) in blood and a variety of diseases has been investigated. MiRNA-based liquid biopsy has attracted much attention, and cancer-specific miRNAs have been reported. However, the results of analyses of the expression of these miRNAs vary among studies. The reproduction of results regarding miRNA expression levels could be difficult if there are differences in the data acquisition process. Previous studies have shown that the anticoagulant type used during plasma preparation and sample storage conditions could contribute to differences in measured miRNA levels. Thus, the impact of these preanalytical conditions on comprehensive miRNA expression profiles was examined. First, the miRNA expression profiles of samples obtained from healthy volunteers were analyzed using next-generation sequencing. Based on an analysis of the library concentration, human genome identification rate, ratio of unique sequences and expression profiles, the optimal preanalytical conditions for obtaining highly reproducible miRNA expression profiles were established. The optimal preanalytical conditions were as follows ethylenediaminetetraacetic acid (EDTA) as the anticoagulant, whole-blood storage at room temperature within 6 hours, and plasma storage at 4°C or -20°C within 30 days. Next, plasma samples were collected from 60 cancer patients (3 facilities × 20 patients/facility), and miRNA expression profiles were analyzed. There were no significant differences in measurements except in the expression of erythrocyte-derived hsa-miR-451a. However, the variation in hsa-miR-451a levels was smaller among facilities than among individuals. This finding suggests that samples obtained from the same facility could show significantly different degrees of hemolysis across individuals. We found that the standardization of anticoagulant use and storage conditions contributed to reducing the variation in sample quality across facilities. The findings from this study could be useful in developing protocols for collecting samples from multiple facilities for cancer screening tests.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: MicroARNs Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: MicroARNs Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Japón